Eli Lilly and Company

Category

Virtual Patient Engagement During Worldwide Pandemic Produces Data Highlighting the Impact of COVID-19 on People Living with Rheumatic Disease

UPPER NYACK, NY (November 2, 2020) – This week CreakyJoints®, the digital patient community for people with all forms of arthritis and part of the Global Healthy Living Foundation (GHLF), is presenting data collected during the worldwide COVID-19...

Eli Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients

Eli Lilly and Company announced today that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, in hospitalized adults...

NYU Langone Among First to Treat COVID-19 Patients with Novel Antibody Arising out of UBC Spinoff Platform & Rapid Lilly Drug Development

NYU Grossman School of Medicine recently began treating patients in a clinical trial to determine whether an antibody therapy known as LY-CoV555 can safely reduce COVID-19 severity. Sponsored by Eli Lilly and Company, this experimental treatment consists of...

Pin It on Pinterest